research APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
JAK inhibitors may help improve symptoms in adults with APECED.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch The type of androgenetic alopecia and quality of life (QoL) in male patients
More severe hair loss worsens quality of life in men.
research Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
research Study of quality of life in patients with premature graying of hair in Western Indian population
Premature graying of hair significantly harms psychological and social wellbeing.
research Dermal lymphatic dilation in a mouse model of alopecia areata
Mice with alopecia areata had wider lymphatic vessels in their skin.
research Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients
Dutasteride effectively and safely treats male hair loss for over a year.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas
Understanding patients' views on their illness can help improve their disease management.
research Clinical and Trichoscopic Patterns of Hair Loss in Systemic Lupus Erythematosus and its Correlation with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research 070 Bacillary Load and Reactional States in Leprosy - A Surge in Severity the COVID Era?
The COVID-19 pandemic has led to more severe cases of Leprosy due to delayed medical care.
research Factors associated with quality of life in patients with central centrifugal cicatricial alopecia: A cross-sectional study
Younger age, longer disease duration, frequent wig use, and lower education levels worsen quality of life in CCCA patients.
research Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients
Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
research [ADAPTIVE REGULATORY MECHANISMS OF ALOPECIA AREATA].
Alopecia areata progression is linked to stress and hormone changes, suggesting new treatment targets.
research Global burden of alopecia areata from 1990 to 2019 and emerging treatment trends analyzed through GBD 2019 and bibliometric data
Alopecia areata affects women and young adults most, with low SDI regions seeing the highest increase, and new treatments like JAK inhibitors are being explored.
research SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
A new tool simplifies alopecia areata severity scoring but needs validation.
research In vivo CD44‐CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance
The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Clinicopathological study of discoid lupus erythematosus.
Discoid Lupus Erythematosus is more common in women aged 31-40, often worsened by sunlight, and confirmed by specific lab tests.
research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis
Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
research Low-level light therapy using a helmet-type device for the treatment of androgenetic alopecia
Helmet-like device safely increases hair density for people with hair loss.
research The impact of alopecia areata on patients' daily lives: A study using social media in France
Alopecia areata significantly affects patients' lives, causing physical, psychological, social, and financial challenges.
research ‘The psychosocial burden of alopecia areata and androgenetica’: a cross‐sectional multicentre study among dermatological out‐patients in 13 European countries
People with hair loss conditions experience more anxiety, depression, and a lower quality of life than those without these conditions.
research An occupational perspective of the lived experience of individuals with Alopecia Areata: A scoping review
Alopecia Areata affects daily life but can lead to new activities.
research Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
research No increased risk of alopecia in ankylosing spondylitis patients: A population‐based cohort study in Taiwan
People with ankylosing spondylitis in Taiwan don't have a higher chance of getting alopecia.
research Using artificial intelligence to compute Severity of Alopecia Tool scores
AI can accurately measure hair loss severity in alopecia areata.
research Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
research Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Sham Device–Controlled Multicenter Trial
Low-level light therapy safely improves hair growth and thickness for androgenetic alopecia.